Pinned post
What is human existence, but our daily quest to defend our domain from entropy?
Rafael Fonseca MD π¦πΊπΈππ²π½
Verified account This account is verified. Learn more@Rfonsi1
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement
2.6K Following 16K Followers 21K Posts
Latest posts 5
I will be speaking at the IMF Myeloma Community Workshop in Phoenix, AZ on 11/14! Join us to get informed on treatments at diagnosis, maintenance therapy, managing side effects, expert Q&A, & more. Register at myeloma.org/events/phoenixβ¦
@imfmyeloma
#myeloma #multiplemyeloma #mms
@imfmyeloma
#myeloma #multiplemyeloma #mms
I have a patient with true non-secretory disease, even by mass spec. He progressed, and we started following peripheral blood MRD with clonSEQ. It showed progression and response to treatment (Tec+Dara). Nicely complements bone marrow testing.
#mmsm
#mmsm
TRIlogy-1 study of trispecific antibody shows high levels of activity. Median prior LOT3 #IMS26 #mmsm
Congratulations to the @PericaKarlo lab! They identified why cilta-cel is superior to ide-cel, and it is not the binding but the promoter used (EF1Ξ± > MND). I think this is why toxicity may be higher.
CARTs can be like a double-edged sword! The more active the CART (expansive & cytotoxic), the higher the risk of delayed neurotoxicity.
CARTs can be like a double-edged sword! The more active the CART (expansive & cytotoxic), the higher the risk of delayed neurotoxicity.
Now online @NatureComms, our manuscript describing why the myeloma CAR T cell cilta-cel is more effective than a very similar CAR, ide-cel.View quoted post on X
Led by the very talented Kevin Herrera and Sneha Mitra, and in collaboration with the Leslie Laboratory.
@MSKCancerCenter @szusmani
